Latest

• Antimicrobial drug consumption in the Russian Federation (2008–2022): pharmacoepidemiological study

  Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(4):395-400

• Report of the Russian database on adverse drug reactions for COVID-19-related drugs with a focus on favipiravir

  Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(1):26-33

• A systematic review and meta-analysis of the safety of anti-interleukin therapy in COVID-19

  Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(2):93-107

• Problems of assessing economic effectiveness of antimicrobial agents: an experience of the Russian Federation

  Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(1):23-29

• Combination of invasive aspergillosis and mucormycosis in children: a case report and the results of a multicenter study

  Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(1):14-22

• Safety profile assessment of drug products used for the pathogenetic treatment of COVID19

  Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(3):314-329

• Treatment of COVID19 with antimalarial medicines: clinical pharmacology analysis

  Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(3):164-174

• Integrated analysis of antibiotic consumption in the hospital segment of Saint-Petersburg in 2014–2018

  Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(3):238-244

• Burden of resistant infections caused by S. aureus, E. coli, K. pneumoniae in Russian Federation

  Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(4):310-318

• Calculation of the optimal structure of antibiotic consumption in a hospital based on the predicted antimicrobial resistance in the treatment of uncomplicated acute pyelonephritis

  Clinical Microbiology and Antimicrobial Chemotherapy. 2018; 20(3):223-231

• Simulation of bacterial resistance for different antibiotic consumption strategies based on the Escherichia coli resistance to cephalosporins

  Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(4):321-326

• Analysis of effectiveness criteria in pharmacoeconomic studies of antimicrobial agents proposed for inclusion in the Russian essential drug list in the 2014 -2016

  Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(3):260-264

• Pharmacoepidemiology of antimicrobial agents in pregnant women: a non-interventional retrospective study

  Clinical Microbiology and Antimicrobial Chemotherapy. 2017; 19(1):67-72

• Prognostic Model of Microbial Resistance Based on the Relationship between Antibiotic Resistance and Consumption

  Clinical Microbiology and Antimicrobial Chemotherapy. 2016; 18(3):200-211

• Systematic Review of Mathematical Models Used for Predicting Bacterial Resistance

  Clinical Microbiology and Antimicrobial Chemotherapy. 2014; 16(2):137-143

• Pharmacoeconomic Analysis of Anidulafungin (Eraxis®) Use in the Treatment of Invasive Candidiasis

  Clinical Microbiology and Antimicrobial Chemotherapy. 2012; 14(3):235-244

• Pharmacoeconomic Analysis of Micafungin (Mycamin®) Use in the Treatment of Patients with Invasive Candidiasis

  Clinical Microbiology and Antimicrobial Chemotherapy. 2011; 13(3):267-278

• Health Economic Issues of the Treatment of HIV-infection and AIDS

  Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(1):67-76

• Clinical and Pharmacoeconomic Analysis of the Treatment of Invasive Candidiasis in Intensive Care Units

  Clinical Microbiology and Antimicrobial Chemotherapy. 2009; 11(3):264-274

• Clinical and Economical Expediency of Posaconazole Comparing with Fluconazole and Itraconazole in Primary Prophylaxis of Systemic Mycoses in Severe Neutropenic Patients

  Clinical Microbiology and Antimicrobial Chemotherapy. 2009; 11(2):170-182

• Analysis of Antifungal Agents Consumption in Large Clinic

  Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(4):355-361

• Efficacy and Safety of Caspofungin in Hematological Patients with Invasive Aspergillosis

  Clinical Microbiology and Antimicrobial Chemotherapy. 2007; 9(2):153-161

• Efficacy and Safety of Combined Antimycotic Therapy of Invasive Aspergillosis in Children

  Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(4):383-388

• Clinical and Pharmacoeconomic Analysis of the Fluconazole Use for the Prophylaxis of Invasive Candidiasis in Very-Low-Birth Weight Infants

  Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(3):270-279

• Efficacy and Safety of Caspofungin in Children with Invasive Fungal Infections

  Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(2):193-200

• Candida Infections in Very-Low-Birth-Wieight Neonates

  Clinical Microbiology and Antimicrobial Chemotherapy. 2005; 7(2):189-196

• Risk Factors for Development of Candidemia in Neonates with Gestational Age Less Than 32 Weeks

  Clinical Microbiology and Antimicrobial Chemotherapy. 2005; 7(1):97-102

• Prophylactic and Empirical Use of Antifungals in Neonates

  Clinical Microbiology and Antimicrobial Chemotherapy. 2003; 5(4):354-359

• Candidemia In Hospitalized Patients In Saint-Petersburg

  Clinical Microbiology and Antimicrobial Chemotherapy. 2002; 4(1):15-21